HK1109767A1 - Quaternary ammonium salts as m3 antagonists - Google Patents
Quaternary ammonium salts as m3 antagonistsInfo
- Publication number
- HK1109767A1 HK1109767A1 HK08100466.7A HK08100466A HK1109767A1 HK 1109767 A1 HK1109767 A1 HK 1109767A1 HK 08100466 A HK08100466 A HK 08100466A HK 1109767 A1 HK1109767 A1 HK 1109767A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- antagonists
- quaternary ammonium
- ammonium salts
- compounds
- muscarinic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0428418.8A GB0428418D0 (en) | 2004-12-24 | 2004-12-24 | Organic compounds |
| PCT/EP2005/013897 WO2006066929A1 (en) | 2004-12-24 | 2005-12-22 | Quaternary ammonium salts as m3 antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1109767A1 true HK1109767A1 (en) | 2008-06-20 |
Family
ID=34130968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK08100466.7A HK1109767A1 (en) | 2004-12-24 | 2008-01-14 | Quaternary ammonium salts as m3 antagonists |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8153669B2 (xx) |
| EP (1) | EP1831208B1 (xx) |
| JP (1) | JP2008525359A (xx) |
| KR (1) | KR101259654B1 (xx) |
| CN (1) | CN101080405B (xx) |
| AT (1) | ATE521606T1 (xx) |
| AU (1) | AU2005318424B2 (xx) |
| BR (1) | BRPI0519292A2 (xx) |
| CA (1) | CA2589133A1 (xx) |
| ES (1) | ES2370832T3 (xx) |
| GB (1) | GB0428418D0 (xx) |
| HK (1) | HK1109767A1 (xx) |
| MX (1) | MX2007007722A (xx) |
| PL (1) | PL1831208T3 (xx) |
| PT (1) | PT1831208E (xx) |
| RU (1) | RU2394031C2 (xx) |
| WO (1) | WO2006066929A1 (xx) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0428416D0 (en) | 2004-12-24 | 2005-02-02 | Novartis Ag | Organic compounds |
| BRPI0807615A8 (pt) | 2007-02-23 | 2017-12-05 | Theravance Inc | Compostos de difenilmetil amônico quaternário úteis como antagonistas de receptor muscarínico |
| CN101796026B (zh) | 2007-09-07 | 2013-10-23 | 施万制药 | 可用作毒蕈碱受体拮抗剂的含胍化合物 |
| EP2222637A1 (en) | 2007-12-14 | 2010-09-01 | Theravance, Inc. | Amidine-containing compounds useful as muscarinic receptor antagonists |
| DE102008020746A1 (de) * | 2008-04-25 | 2009-10-29 | Saltigo Gmbh | Verfahren zur Herstellung von quarternären Salzen von Piperidyl Estern der Mandelsäure |
| JP6363616B2 (ja) | 2012-12-19 | 2018-07-25 | ノバルティス アーゲー | オートタキシン阻害剤 |
| TR201808040T4 (tr) | 2013-03-15 | 2018-06-21 | Bodor Laboratories Inc | Hiperhidrozun tedavisine yönelik yumuşak antikolinerjik esterler. |
| JPWO2015122031A1 (ja) * | 2014-02-17 | 2017-03-30 | 株式会社Ｌｔｔバイオファーマ | メペンゾラート光学活性体及びそれを有効成分とする慢性閉塞性肺疾患改善剤 |
| US20150259283A1 (en) | 2014-03-13 | 2015-09-17 | Brickell Biotech, Inc. | Formulation for soft anticholinergic analogs |
| US20170037030A1 (en) | 2014-04-24 | 2017-02-09 | Novartis Ag | Autotaxin inhibitors |
| US10472664B2 (en) | 2014-10-03 | 2019-11-12 | Institute For Cancer Research | Screening assay for identification of poly(ADP-ribose) polymerase 1 inhibitors |
| CA2963422A1 (en) | 2014-10-03 | 2016-04-07 | Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center | Poly(adp-ribose) polymerase 1 inhibitors structurally unrelated to nad |
| EP3325487B1 (en) | 2015-07-21 | 2021-05-05 | Bodor Laboratories, Inc. | Formulation for soft anticholinergic analogs |
| TWI767507B (zh) | 2016-07-21 | 2022-06-11 | 美商波德實驗股份有限公司 | 軟性抗膽鹼類似物之製劑 |
| AU2021236130A1 (en) * | 2020-03-11 | 2022-09-22 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2746966A (en) | 1953-11-02 | 1956-05-22 | Lakeside Lab Inc | Esters of bis-(nu-substituted-3-hydroxypiperidinium) alkanes |
| GB833820A (en) * | 1957-10-17 | 1960-04-27 | Beecham Res Lab | Improvements in or relating to the preparation of pyrrolidyl esters and quaternary compounds thereof |
| US2956062A (en) * | 1959-02-26 | 1960-10-11 | Robins Co Inc A H | Esters of amino alcohols |
| JPS6018661B2 (ja) | 1976-01-01 | 1985-05-11 | 太田製薬株式会社 | １−（１，３−ジオキソラン−４−イルメチル）ピペリジノ−ル誘導体 |
| JPS5427570A (en) | 1977-07-30 | 1979-03-01 | Ota Pharma | Stereoisomer of 44acyloxyy11 alkyll11*1*33dioxolanee44 ylmethyl* pideridinium salt derivative |
| JPS5679688A (en) | 1979-12-04 | 1981-06-30 | Ota Seiyaku Kk | 4-acyloxy-1- 1,3-dioxoran-2-ylmethyl piperidine derivative and its production |
| JPS5835177A (ja) | 1981-08-26 | 1983-03-01 | Dainippon Pharmaceut Co Ltd | ２−環状アミノ−２−（１，２−ベンズイソキサゾ−ル−３−イル）酢酸エステル類並びにその酸付加塩類および第４級アンモニウム塩類 |
| JPS58208270A (ja) | 1982-05-28 | 1983-12-03 | Dainippon Pharmaceut Co Ltd | α−環状アミノフエニル酢酸エステル類並びにその酸付加塩類及び第４級アンモニウム塩類 |
| GB9023023D0 (en) | 1990-10-23 | 1990-12-05 | Barlow Richard B | Pharmaceutical compositions |
| RU2238936C2 (ru) | 1996-11-11 | 2004-10-27 | Кристиан Р. НОЕ | Энантиомерно чистые основные эфиры арил-циклоалкилгидроксикарбоновых кислот, способ их получения и применение в лекарственных средствах |
| WO2002004402A1 (fr) * | 2000-07-11 | 2002-01-17 | Banyu Pharmaceutical Co., Ltd. | Derives d'ester |
| ES2206021B1 (es) * | 2002-04-16 | 2005-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de pirrolidinio. |
| EP1583741A1 (en) * | 2002-12-23 | 2005-10-12 | Ranbaxy Laboratories, Limited | 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists |
| PE20050231A1 (es) * | 2003-06-24 | 2005-05-20 | Novartis Ag | Derivados de piperidinium y pirrolidinium como antagonistas del receptor muscarinico m3 |
| EP1781607A2 (en) * | 2004-08-19 | 2007-05-09 | Ranbaxy Laboratories Limited | Pyrrolidine derivatives as muscarinic receptor antagonists |
-
2004
- 2004-12-24 GB GBGB0428418.8A patent/GB0428418D0/en not_active Ceased
-
2005
- 2005-12-22 CN CN2005800429764A patent/CN101080405B/zh not_active Expired - Fee Related
- 2005-12-22 KR KR1020077014261A patent/KR101259654B1/ko not_active IP Right Cessation
- 2005-12-22 EP EP05820639A patent/EP1831208B1/en not_active Not-in-force
- 2005-12-22 US US11/721,989 patent/US8153669B2/en not_active Expired - Fee Related
- 2005-12-22 BR BRPI0519292-7A patent/BRPI0519292A2/pt not_active IP Right Cessation
- 2005-12-22 ES ES05820639T patent/ES2370832T3/es active Active
- 2005-12-22 PT PT05820639T patent/PT1831208E/pt unknown
- 2005-12-22 CA CA002589133A patent/CA2589133A1/en not_active Abandoned
- 2005-12-22 PL PL05820639T patent/PL1831208T3/pl unknown
- 2005-12-22 RU RU2007128085/04A patent/RU2394031C2/ru not_active IP Right Cessation
- 2005-12-22 AT AT05820639T patent/ATE521606T1/de active
- 2005-12-22 AU AU2005318424A patent/AU2005318424B2/en not_active Ceased
- 2005-12-22 WO PCT/EP2005/013897 patent/WO2006066929A1/en active Application Filing
- 2005-12-22 JP JP2007547368A patent/JP2008525359A/ja active Pending
- 2005-12-22 MX MX2007007722A patent/MX2007007722A/es active IP Right Grant
-
2008
- 2008-01-14 HK HK08100466.7A patent/HK1109767A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005318424A1 (en) | 2006-06-29 |
| MX2007007722A (es) | 2007-08-14 |
| CN101080405A (zh) | 2007-11-28 |
| ES2370832T3 (es) | 2011-12-23 |
| EP1831208A1 (en) | 2007-09-12 |
| KR101259654B1 (ko) | 2013-04-30 |
| US20090227590A1 (en) | 2009-09-10 |
| KR20070089953A (ko) | 2007-09-04 |
| CN101080405B (zh) | 2011-05-11 |
| RU2394031C2 (ru) | 2010-07-10 |
| JP2008525359A (ja) | 2008-07-17 |
| CA2589133A1 (en) | 2006-06-29 |
| BRPI0519292A2 (pt) | 2009-01-06 |
| US8153669B2 (en) | 2012-04-10 |
| EP1831208B1 (en) | 2011-08-24 |
| ATE521606T1 (de) | 2011-09-15 |
| PL1831208T3 (pl) | 2012-01-31 |
| AU2005318424B2 (en) | 2009-10-08 |
| WO2006066929A1 (en) | 2006-06-29 |
| PT1831208E (pt) | 2011-10-31 |
| RU2007128085A (ru) | 2009-01-27 |
| GB0428418D0 (en) | 2005-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1109767A1 (en) | Quaternary ammonium salts as m3 antagonists | |
| TW200505920A (en) | Organic compounds | |
| MX2007007720A (es) | Derivados de pirrolidinio como receptores m3 muscarinicos. | |
| JO2613B1 (ar) | مركبات عضوية | |
| TW200519106A (en) | Organic compounds | |
| MX2009004715A (es) | Compuestos heterociclicos como agentes antiinflamatorios. | |
| TW200517386A (en) | Organic compounds | |
| TW200617009A (en) | Organic compounds | |
| TN2010000167A1 (en) | Organic compounds | |
| GB0305152D0 (en) | Organic compounds | |
| HK1125358A1 (en) | Substituted cyclohexylmethyl derivatives | |
| MX2009004780A (es) | Derivados de quiniclidina de acido (hetero) arilcicloheptano carboxilico como antagonistas del receptor muscarinico. | |
| GEP20104964B (en) | 3-aminocarbazole compounds, pharmaceutical composition containing the same and method for the preparation thereof | |
| MXPA05013823A (es) | Derivados de pirrolidinio y piperidino como ligandos para el receptor m3 muscarinico. | |
| UA98772C2 (ru) | Производные циклопропиламина как модуляторы н3-гистаминового рецептора | |
| TNSN05279A1 (en) | Quinuclidine derivatives binding to mucarinic m3 receptors | |
| TNSN06410A1 (en) | Pyrrolopyridine derivatives and their use as crth2 antagonists | |
| DE602005024828D1 (de) | Rezeptors wirken | |
| UA94242C2 (ru) | Производные бензотиазолциклобутиламина и их применение как лигандов рецепторов гистамина-3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20151222 |